Total Androgen Blockade Versus a Luteinizing Hormone-Releasing Hormone Agonist Alone in Men With High-Risk Prostate Cancer Treated With Radiotherapy

International Journal of Radiation Oncology Biology Physics

Volumn 76, Issue 5, 2010, Pages 1439-1444

  Nanda, Akash ^a   Chen, Ming Hui ^b   Moran, Brian J ^c   Braccioforte, Michelle H ^c   Dosoretz, Daniel ^d   Salenius, Sharon ^d   Katin, Michael ^d   Ross, Rudi ^d   D'Amico, Anthony V ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY OF CONNECTICUT   (United States)

^c Prostate Cancer Foundation of Chicago   (United States)

^d 21ST CENTURY ONCOLOGY   (United States)

Author keywords

Androgen suppression therapy; Brachytherapy; External beam radiotherapy; Prostate cancer; Prostate cancer specific mortality

Indexed keywords

ANDROGEN SUPPRESSION; BRACHYTHERAPY; CONFIDENCE INTERVAL; EXTERNAL BEAM RADIOTHERAPY; GLEASON SCORES; HAZARD RATIO; INTER QUARTILE RANGES; MONO-THERAPY; MULTIVARIABLE REGRESSION ANALYSIS; PROGNOSTIC FACTORS; PROSTATE CANCERS; PROSTATE SPECIFIC ANTIGEN;

ANTIGENS; ONCOLOGY; REGRESSION ANALYSIS;

RADIOTHERAPY;

BICALUTAMIDE; CARBON 131; FLUTAMIDE; GOSERELIN; IODINE 125; LEUPRORELIN; PALLADIUM 103; PROSTATE SPECIFIC ANTIGEN; RADIOISOTOPE; UNCLASSIFIED DRUG;

ADULT; AGE DISTRIBUTION; AGED; ANDROGEN DEPRIVATION THERAPY; ANTIANDROGEN THERAPY; ARTICLE; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RISK; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE CLASSIFICATION; DISEASE SEVERITY; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; GLEASON SCORE; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; INTERSTITIAL RADIATION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTIMODALITY CANCER THERAPY; PRIORITY JOURNAL; PROGNOSIS; PROSTATE ADENOCARCINOMA; PROTEIN BLOOD LEVEL; RADIATION DOSE; TREATMENT DURATION;

AGED; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; DRUG THERAPY, COMBINATION; FOLLOW-UP STUDIES; GOSERELIN; HUMANS; LEUPROLIDE; MALE; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; REGRESSION ANALYSIS;

EID: 77949544715     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2009.03.034     Document Type: Article

References (31)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2008. CA Cancer J Clin 58 (2008) 71-96
2. Cooperberg M.R., Cowan J., Broering J.M., et al. High-risk prostate cancer in the United States, 1990-2007. World J Urol 26 (2008) 211-218
3. Denham J.W., Steigler A., Lamb D.S., et al. Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: Results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial. Lancet Oncol 6 (2005) 841-850
4. Pilepich M.V., Winter K., John M.J., et al. Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 50 (2001) 1243-1252
5. D'Amico A.V., Manola J., Loffredo M., et al. 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: A randomized controlled trial. JAMA 292 (2004) 821-827
6. Bolla M., Collette L., Blank L., et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): A phase III randomised trial. Lancet 360 (2002) 103-106
7. Pilepich M.V., Winter K., Lawton C.A., et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma-Long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys 61 (2005) 1285-1290
8. Dearnaley D.P., Sydes M.R., Graham J.D., et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: First results from the MRC RT01 randomised controlled trial. Lancet Oncol 8 (2007) 475-487
9. Horwitz E.M., Bae K., Hanks G.E., et al. Ten-year follow-up of radiation therapy oncology group protocol 92-02: A phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol 26 (2008) 2497-2504
10. Crawford E.D., Eisenberger M.A., McLeod D.G., et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 321 (1989) 419-424
11. Eisenberger M.A., Blumenstein B.A., Crawford E.D., et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med 339 (1998) 1036-1042
12. D'Amico A.V., Chen M.H., Renshaw A.A., et al. Risk of prostate cancer recurrence in men treated with radiation alone or in conjunction with combined or less than combined androgen suppression therapy. J Clin Oncol 26 (2008) 2979-2983
13. Mantel N., and Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22 (1959) 719-748
14. Fine J.P., and Gray R.J. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 94 (1999) 496-509
15. D'Amico A.V., Whittington R., Malkowicz S.B., et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280 (1998) 969-974
16. Klein J.P., and Moeschberger M.L. Survival analysis (1997), Springer-Verlag, New York
17. Zelefsky M.J., Yamada Y., Fuks Z., et al. Long-term results of conformal radiotherapy for prostate cancer: Impact of dose escalation on biochemical tumor control and distant metastases-free survival outcomes. Int J Radiat Oncol Biol Phys 71 (2008) 1028-1033
18. Cahlon O., Zelefsky M.J., Shippy A., et al. Ultra-high dose (86.4 Gy) IMRT for localized prostate cancer: Toxicity and biochemical outcomes. Int J Radiat Oncol Biol Phys 71 (2008) 330-337
19. Zelefsky M.J., Chan H., Hunt M., et al. Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer. J Urol 176 (2006) 1415-1419
20. Zelefsky M.J., Marion C., Fuks Z., et al. Improved biochemical disease-free survival of men younger than 60 years with prostate cancer treated with high dose conformal external beam radiotherapy. J Urol 170 (2003) 1828-1832
21. Zelefsky M.J., Fuks Z., Hunt M., et al. High-dose intensity modulated radiation therapy for prostate cancer: Early toxicity and biochemical outcome in 772 patients. Int J Radiat Oncol Biol Phys 53 (2002) 1111-1116
22. Ritter M. Rationale, conduct, and outcome using hypofractionated radiotherapy in prostate cancer. Semin Radiat Oncol 18 (2008) 249-256
23. Roach III M., DeSilvio M., Lawton C., et al. Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413. J Clin Oncol 21 (2003) 1904-1911
24. Pommier P., Chabaud S., Lagrange J.L., et al. Is there a role for pelvic irradiation in localized prostate adenocarcinoma? Preliminary results of GETUG-01. J Clin Oncol 25 (2007) 5366-5373
25. Lawton C.A., DeSilvio M., Roach III M., et al. An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: Updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions. Int J Radiat Oncol Biol Phys 69 (2007) 646-655
26. Wirth M.P., See W.A., McLeod D.G., et al. Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: Results from the second analysis of the early prostate cancer program at median followup of 5.4 years. J Urol 172 (2004) 1865-1870
27. Thole Z., Manso G., Salgueiro E., et al. Hepatotoxicity induced by antiandrogens: A review of the literature. Urol Int 73 (2004) 289-295
28. Sanda M.G., Dunn R.L., Michalski J., et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 358 (2008) 1250-1261
29. Wu A.K., Cooperberg M.R., Sadetsky N., et al. Health related quality of life in patients treated with multimodal therapy for prostate cancer. J Urol 180 (2008) 2415-2422 discussion 2422
30. Dicker A.P. The safety and tolerability of low-dose irradiation for the management of gynaecomastia caused by antiandrogen monotherapy. Lancet Oncol 4 (2003) 30-36
31. D'Amico A.V., Kantoff P.W., and Chen M.H. Aspirin and hormone therapy for prostate cancer. N Engl J Med 357 (2007) 2737-2738